SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo

🎯 Drug Targets

Browse 4 drug targets with druggability analysis, composite scores, and clinical context

4
Targets
0
High Druggability
0.64
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 4Low: 0Unknown: 0
Avg druggability score: 0.486
Clinical Pipeline
Approved: 0Phase III: 3Phase II: 1Phase I: 0Preclinical: 0
Total compounds: 10 · Approved: 0
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Transcription Factor (11) Receptor (11) Ligand (10) Transporter (8) Epigenetic Regulator (8) Kinase (7) Protease (4) Other (4) Chaperone (4)
Druggability Low (100) Medium (62) High (14) Undruggable (6) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=protease — 4 results
MMP2 Matrix metalloproteinase-2 Phase 3
Protease Medium Druggability
Score
0.64
Drug.
0.46
Safety
0.35
Drugs
2
Hyps
1
Papers
22
Small molecule zinc-chelating inhibitors of metalloprotease activity
CASP1 Caspase-1 Phase 2
Protease Medium Druggability
Score
0.64
Drug.
0.46
Safety
0.50
Drugs
3
Hyps
1
Papers
0
Small molecule covalent inhibitor of caspase-1 proteolytic activity
MMP9 Matrix metalloproteinase-9 Phase 3
Protease Medium Druggability
Score
0.64
Drug.
0.54
Safety
0.30
Drugs
2
Hyps
1
Papers
22
Small molecule zinc-chelating inhibitors or antibody-based inhibition
BACE1 Beta-secretase 1 Phase 3
Protease Medium Druggability
Score
0.63
Drug.
0.48
Safety
0.30
Drugs
3
Hyps
8
Papers
0
Small molecule inhibitor of aspartyl protease activity
Exchange | Dashboard